BioMarin: Voxzogo Approval Could Trigger A Lengthy Bull Run For Cash Rich Biotech
damircudic/iStock via Getty Images
Investment Thesis
BioMarin (NASDAQ:BMRN) is a $14.5bn market cap biotech with 6 commercialised drug products, all targeting rare diseases. The San Rafael, California based company has grown its revenues from $750m in…
